Diabetes drug use status after TBIR treatment was as follows for 17 cases (with duplicate use): 8 cases had no prescription, 6 cases used α-glucosidase inhibitors, 3 cases used glucagon-like peptide-1 receptor agonists, 2 cases used insulin, and 2 cases used biguanide. Here, GLP1R is linked to diabetes mellitus.